Drug Trial Radar · NCT07850934
Effect of Melatonin on Pulmonary Hypertension in Full Term Neonates
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Nov 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Ain Shams UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 30, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study 1. To evaluate safety and efficacy of melatonin as an adjuvant therapy to inhaled nitric oxide generated by NO generator in the treatment of pulmonary hypertension in full term neonates. 2. To assess the effect of inhaled nitric oxide and melatonin on cerebral perfusion.
Conditions
- Congenital Peumonia
- Persistent Pulmonary Hypertension of Newborn
- Congenital Diaphragmatic Hernia
Interventions
MelatoninDrug
Melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy
nitric oxide generatorDevice
iNO will be initiated at 20 ppm. The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy.If there is no clinical response, the iNO dose will be increased to up to 40 ppm. If after 30 minutes there is no clinical response, iNO will be discontinued
Primary outcomes
What the sponsor says the trial is designed to measure.
- melatonin as an adjuvant therapy to iNOTime frame: 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ain Shams University
Cairo, Abbassia, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.